{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:26Z","timestamp":1791308186942,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T00:00:00Z","timestamp":1441152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jnci.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T07:51:50Z","timestamp":1442389910000},"page":"205-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Waleed","family":"Arafat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Naoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jnci.2015.08.003_b0005","doi-asserted-by":"crossref","unstructured":"Society AC. Cancer facts and figures. Atlanta; 2004.","DOI":"10.1016\/S1351-4210(04)00169-6"},{"key":"10.1016\/j.jnci.2015.08.003_b0010","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0022-5347(01)66718-1","article-title":"Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. The American Urological Association","volume":"154","author":"Middleton","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.jnci.2015.08.003_b0015","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.1996.14.8.2258","article-title":"Outcomes of external-beam radiation therapy for prostate cancer: a study of medicare beneficiaries in three surveillance, epidemiology, and end results areas","volume":"14","author":"Fowler","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2015.08.003_b0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0167-8140(99)00100-0","article-title":"Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer","volume":"55","author":"Zelefsky","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jnci.2015.08.003_b0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/CGC.2004.n.022","article-title":"Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?","volume":"3","author":"Rosenberg","year":"2000","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.jnci.2015.08.003_b0030","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.onc.1204318","article-title":"Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL","volume":"20","author":"Belka","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jnci.2015.08.003_b0035","first-page":"1712","article-title":"Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac\/DIABLO release","volume":"63","author":"Kandasamy","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jnci.2015.08.003_b0040","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2003.09.067","article-title":"Apoptosis-modulating agents in combination with radiotherapy-current status and outlook","volume":"58","author":"Belka","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.jnci.2015.08.003_b0045","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.7314\/APJCP.2014.15.5.1905","article-title":"Ionizing radiations induce apoptosis in TRAIL resistant cancer cells: in vivo and in vitro analysis","volume":"15","author":"Silva","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jnci.2015.08.003_b0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/pros.20069","article-title":"Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms","volume":"61","author":"Shankar","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.jnci.2015.08.003_b0055","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0360-3016(02)04488-7","article-title":"An adenovirus encoding proapoptotic bax synergistically radiosensitizes malignant glioma","volume":"55","author":"Arafat","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jnci.2015.08.003_b0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(01)02816-2","article-title":"Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells","volume":"505","author":"Kim","year":"2001","journal-title":"FEBS Lett"},{"issue":"20","key":"10.1016\/j.jnci.2015.08.003_b0065","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1007\/s00253-013-5227-9","article-title":"TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology","volume":"97","author":"Farooqi","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.jnci.2015.08.003_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jnci.2015.08.003_b0075","doi-asserted-by":"crossref","first-page":"25417","DOI":"10.1074\/jbc.272.41.25417","article-title":"Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL","volume":"272","author":"MacFarlane","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jnci.2015.08.003_b0080","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jnci.2015.08.003_b0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/75045","article-title":"Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand","volume":"6","author":"Jo","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jnci.2015.08.003_b0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jnci.2015.08.003_b0095","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1074-7613(00)80400-8","article-title":"Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway","volume":"7","author":"Chaudhary","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jnci.2015.08.003_b0100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1074-7613(00)80401-X","article-title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB","volume":"7","author":"Schneider","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jnci.2015.08.003_b0105","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jnci.2015.08.003_b0110","first-page":"3731","article-title":"Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and\/or radiation therapy in a human breast cancer model","volume":"9","author":"Buchsbaum","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jnci.2015.08.003_b0115","first-page":"145","article-title":"Treatment with mTRA-8 anti-DR5 monoclonal antibody with or without chemotherapy inhibits human colon cancer xenograft growth in athymic nude mice","volume":"44","author":"Buchsbaum","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.jnci.2015.08.003_b0120","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1074\/jbc.M005196200","article-title":"Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis","volume":"276","author":"Nesterov","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jnci.2015.08.003_b0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.10155","article-title":"Synergy is achieved by complementation with Apo2L\/TRAIL and actinomycin D in Apo2L\/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance","volume":"53","author":"Ng","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.jnci.2015.08.003_b0130","first-page":"759","article-title":"Pretreatment with paclitaxel enhances Apo-2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jnci.2015.08.003_b0135","first-page":"1133","article-title":"The sequential treatment with ionizing radiation followed by TRAIL\/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice","volume":"24","author":"Shankar","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jnci.2015.08.003_b0140","unstructured":"Stump DC, Parrott J, de Santis K. Human Genome Sciences initiates clinical development of a novel anticancer drug. Human Genome Sciences Press Release; 2002."},{"key":"10.1016\/j.jnci.2015.08.003_b0145","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1172\/JCI3492","article-title":"LIGHT, a novel ligand for lymphotoxin \u00df receptor and TR2\/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer","volume":"102","author":"Zhai","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jnci.2015.08.003_b0150","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jnci.2015.08.003_b0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","article-title":"The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain","volume":"7","author":"Degli-Esposti","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jnci.2015.08.003_b0160","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.jnci.2015.08.003_b0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jnci.2015.08.003_b0170","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/13543784.10.8.1521","article-title":"Concepts in the use of TRAIL\/Apo2L: an emerging biotherapy for myeloma and other neoplasias","volume":"10","author":"Mitsiades","year":"2001","journal-title":"Expert Opin Invest Drugs"},{"issue":"5","key":"10.1016\/j.jnci.2015.08.003_b0175","first-page":"1371","article-title":"Prostate cancer: leading and misleading routes to TRAIL of death","volume":"27","author":"Farooqi","year":"2014","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.jnci.2015.08.003_b0180","first-page":"3093","article-title":"Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand\/Apo-2 ligand-mediated apoptosis in renal cell carcinoma","volume":"62","author":"Griffith","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jnci.2015.08.003_b0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2001.19.1.44","article-title":"Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jnci.2015.08.003_b0190","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/nar\/gkh783","article-title":"Portrait of transcriptional responses to ultraviolet and ionizing radiation in human cells","volume":"32","author":"Rieger","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.jnci.2015.08.003_b0195","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/1541-7786.MCR-10-0133","article-title":"Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells","volume":"9","author":"Amm","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"18 Pt 2","key":"10.1016\/j.jnci.2015.08.003_b0200","doi-asserted-by":"crossref","first-page":"5535s","DOI":"10.1158\/1078-0432.CCR-07-1075","article-title":"Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer","volume":"13","author":"DeRosier","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jnci.2015.08.003_b0205","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1148\/radiol.2483071740","article-title":"Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody","volume":"248","author":"Kim","year":"2008","journal-title":"Radiology"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036215000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036215000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T12:50:21Z","timestamp":1567169421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036215000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1110036215000874"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2015.08.003","relation":{},"ISSN":["1110-0362"],"issn-type":[{"value":"1110-0362","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the Egyptian National Cancer Institute","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnci.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}